Aug 12, 2015 by Brian Orelli, PhDArena Pharmaceuticals' Belviq Sales Are Better Than They Appear (But They're Still Not Great) Declining quarter-over-quarter sales look bad, but investors needn't freak out.
Aug 11, 2015 by Brian Orelli, PhDExelixis Earnings: No Time to ReminisceDespite positive phase 3 data last month, the biotech's earnings release was focused on what's ahead.
Aug 7, 2015 by Brian Orelli, PhDBluebird Bio UpdatesAs usual, an "earnings" report from the biotech turns into a review of recent events.
Aug 6, 2015 by Brian Orelli, PhDAlnylam Pharmaceuticals Injects Some Bad News Into Its Earnings ReportInjection-site reactions cause three patients to drop out of a clinical trial for revusiran.
Aug 6, 2015 by Brian Orelli, PhDA Breakup at Emergent BioSolutionsThe biodefense specialist announced plans to spin off its biosciences division.
Aug 5, 2015 by Brian Orelli, PhDPacific Biosciences' Lumpy RevenueMilestone payments from Roche put investors on a roller coaster ride.
Aug 4, 2015 by Brian Orelli, PhDStill Waiting for Profitability at Genomic HealthProspects for reimbursement are improving.
Aug 4, 2015 by Brian Orelli, PhDIsis' News-Filled WeekThe biotech announces a new partnership, clinical trial results, and earnings over the course of two days.
Aug 4, 2015 by Brian Orelli, PhDMomenta Has MomentumThe launch of Glatopa is off to a good start and the biotech has more drugs in the works.
Aug 3, 2015 by Brian Orelli, PhDBioMarin Pharmaceuticals: Lumpy Sales Strike AgainThe biotech beats on revenue, but it's where the sales came from that made for a solid-but-not-outstanding quarter.
Jul 31, 2015 by Brian Orelli, PhD3 Things to Watch as Genomic Health Reports EarningsTest usage, reimbursement, and the move into liquid biopsy are all important for the cancer-test company.
Jul 31, 2015 by Brian Orelli, PhDImmunoGen: Back to a Development-Stage BiotechWith the biotech no longer collecting Kadcyla royalties, the pipeline becomes the focus of the release of quarterly earnings.
Jul 31, 2015 by Brian Orelli, PhDStill Profitless in Seattle GeneticsBut a growth opportunity is around the corner.
Jul 30, 2015 by Brian Orelli, PhDThe Tale of Two Teva PharmaceuticalsRevenue down, earnings up. At least it wasn't the other way around.
Jul 30, 2015 by Brian Orelli, PhDAn Animal of a Quarter for IDEXX The animal-testing company posts substantial growth at constant currencies.
Jul 30, 2015 by Brian Orelli, PhDQiagen's TransformingAs sales of its human papillomavirus testing continue to shrink, the test maker grows in other areas.
Jul 29, 2015 by Brian Orelli, PhDOne Last Combined Earnings Release for Baxter and BaxaltaThe combined release makes it hard for investors to gauge the parent company’s future prospects.
Jul 29, 2015 by Brian Orelli, PhDVertex Pharmaceuticals Rolls AlongSolid quarter, but Orkambi sales in future quarters will dictate the biotech’s fate.
Jul 27, 2015 by Brian Orelli, PhD5 Things Biogen's Management Wants You to KnowTecfidera, more Tecfidera, and how to replace Tecfidera growth.
Jul 24, 2015 by Brian Orelli, PhDBiogen's Terrible, Horrible, No Good, Very Bad WeekMixed data and lower-than-expected earnings make for a bad week.
